07:00 , Jul 9, 2007 |  BC Week In Review  |  Clinical News

Lomucin talniflumate: Development discontinued

GENR stopped a double-blind, placebo-controlled Phase II trial and discontinued development of Lomucin after a data monitoring committee (DMC) said there would be no additional benefit to further enrollment in the study. GENR has an...
00:22 , Jul 6, 2007 |  BC Extra  |  Company News

Genaera ends Lomucin, squalamine trials

GENR discontinued studies of Lomucin talniflumate for cystic fibrosis and squalamine lactate to treat prostate cancer. The decision to end the Phase II trial of Lomucin, an orally absorbed antagonist of calcium-activated chloride channel (gob-5),...
07:00 , Sep 26, 2005 |  BC Week In Review  |  Clinical News

Lomucin: Phase II started

GENR began a double-blind, placebo-controlled, European Phase II trial in 200 patients. Genaera Corp. (GENR), Plymouth Meeting, Penn.   Bago Group , Buenos Aires, Argentina   Product: Lomucin   Business: Pulmonary   Molecular target: hCLCA1...
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

Lomucin: Phase II start

GENR will start this quarter a double-blind, placebo-controlled, European Phase II trial of Lomucin in 200 patients. Genaera Corp. (GENR), Plymouth Meeting, Penn.   Bago Group , Buenos Aires, Argentina   Product: Lomucin   Business:...
00:53 , Apr 19, 2005 |  BC Extra  |  Clinical News

Genaera starts Lomucin pivotal Phase II

GENR will start a double-blind pivotal Phase II trial of Lomucin talniflumate to treat cystic fibrosis (CF) this quarter. The primary endpoint of the European trial in 200 patients is Forced Expiratory Volume in one...